Present status of research on drug interactions between fluoropyrimidines and warfarin
10.3760/cma.j.issn.1008-5734.1014.04.011
- VernacularTitle:氟尿嘧啶类抗肿瘤药物与华法林相互作用研究现状
- Author:
Bishan HE
1
;
Zichao LIN
1
;
Hongbing HUANG
1
;
Tao LIU
1
;
Fenghua WANG
1
Author Information
1. 华南肿瘤学国家重点实验室 中山大学附属肿瘤医院药学部, 广州,510060
- Publication Type:Journal Article
- Keywords:
Drug interactions;
Fluorouracil;
Warfarin
- From:
Adverse Drug Reactions Journal
2014;(4):232-236
- CountryChina
- Language:Chinese
-
Abstract:
Chemotherapeutic regimens based on fluoropyrimidines such as 5-fluorouracil, capecitabine,and tegafur,gimeracil and oteracil potassium(S1)are widely used in a variety of solid tumor therapy. Cancer patients are high-risk persons of thrombosis and anticoagulant therapy is recommended for patients with thrombosis or with risk factors of thrombosis. At present,warfarin is the widely used oral anticoagulant. There are drug interactions when 5-fluorouracil, capecitabine, and S1 are given in combination with warfarin and it may lead to elevated international normalized ratio and symptoms of bleeding. Most patients could recover after warfarin withdrawal,dosage reducing,and replacement with low-molecular heparin. However, a few patients may require blood transfusion. The mechanism of drug interactions due to concomitant use of fluoropyrimidines and warfarin remains unclear and may be related to inhibiting activity of metabolic enzyme of warfarin-hepatic cytochrome P450 1C9 by 5-fluorouracil or its metabolites.
